Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs BDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

BDX Overall Winner 6-Pillar Tally: PMI 0 – 6 BDX Matrix Metrics: PMI 3 – 7 BDX

As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas BDX carries 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin).

  • Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs BDX
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
BDX NYSE Head-to-Head Winner
Becton, Dickinson and Co.
Surgical & Medical Instruments & Apparatus
$212.68
-1.57% 1D
Market Cap $58.9B
TTM Revenue $19.5B
Forward P/E 16.0x
Beta / 30D Vol 0.16β · 26% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 24.0 Fund 48.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.7% over 20 days), RSI 63
RSI-14: 62.7 · SMA20: $207.49 · SMA50: $193.75

6-Pillar Scorecard Institutional Category Breakdown (PMI 0 – 6 BDX)

Columns: Metric · PMI · BDX
1. Valuation Multiples BDX
Forward P/E N/M 16.0x
Trailing P/E 2.9x 42.7x
PEG Ratio N/M 0.99x
EV / Revenue 3.2x 4.2x
2. Growth & Scale BDX
Revenue Growth (YoY) +38.6% -10.5%
Earnings Growth (YoY) +0.0% +47.6%
TTM Revenue (USD) $6.3M $19.5B
Market Cap $17.1M $58.9B
3. Profitability & Quality BDX
Gross Margin 18.6% 47.0%
Operating Margin -248.1% 15.7%
Net Profit Margin 0.0% 5.9%
Return on Equity (ROE) 0.0% 5.7%
4. Balance Sheet & Cash Flow BDX
Cash Generation (TTM) -$17M $3.71B
Cash Flow Margin N/A 19.1%
Net Cash / Leverage $3.2M Net Debt $23.6B Net Debt (0.69x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BDX
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 28.4% (9th %ile)
Put/Call OI Skew N/A 0.41x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat BDX
OpEx & R&D Intensity N/A 31.3% of Rev ($6.09B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (3) vs BDX (7)
Institutional Metric PMI BDX Criterion Row Edge
Market Capitalization
Scale
$17.1M $58.9B Larger Scale BDX
Trailing P/E Ratio
Valuation
2.9x 42.7x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 16.0x Lower Multiple BDX
Revenue Growth (YoY)
Growth
+38.6% -10.5% Higher Growth PMI
Operating Margin (TTM)
Profitability
-248.1% 15.7% Higher Margin BDX
Net Profit Margin
Profitability
0.0% 5.9% Higher Margin BDX
Return on Equity (ROE)
Capital Efficiency
0.0% 5.7% Higher ROE BDX
52-Week Range Position
Momentum
34% ($0–$18) 90% ($140–$220) Stronger Trend BDX
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 0.16β · 26% Vol Lower Realized Risk BDX
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 47.9 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $19.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 47.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev 0.99x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) $3.71B ($23.6B Net Debt (0.69x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDX +44.02 pp
PMI: -34.58% · BDX: +9.44%
3M Horizon PMI +85.49 pp
PMI: +96.26% · BDX: +10.77%
6M Horizon PMI +3395.15 pp
PMI: +3439.33% · BDX: +44.18%
1Y Horizon PMI +137.45 pp
PMI: +148.03% · BDX: +10.58%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue BDX Revenue PMI Op. Margin BDX Op. Margin Margin Leader
FY2018 N/A $16.0B N/A 9.4% BDX
FY2019 N/A $17.3B N/A 10.2% BDX
FY2020 N/A $16.1B N/A 5.7% BDX
FY2021 N/A $19.1B N/A 11.8% BDX
FY2022 N/A $18.9B N/A 12.1% BDX
FY2023 N/A $19.4B N/A 10.9% BDX
FY2024 $0M $20.2B -312.3% 11.9% BDX
FY2025 $0M $21.8B -268.4% 11.8% BDX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDX BREAKOUT
63d in phase · OBV NEUTRAL
Current IV 28.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $212.43 · IV 25.8%

BDX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,243)

Compare $21,243 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 25.8% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $210 / $220 Bull Call Spread

Buy 1x $210C · Sell 1x $220C · 29d

Net Entry $443 Debit
T+5d @ +5% Move +$270 (+61%)
Max Risk / Buffer $443 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $200 / $190 Bull Put Spread

Sell 1x $200P · Buy 1x $190P · 29d

Net Entry $156 Credit
Max Credit / Yield +$156 (+18.5% RoM)
Max Risk / Buffer -6.6% Cushion ($844 Mgn)
5d Edge & Liquidity 78% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BDX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $58.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 31.3% of Rev ($6.09B)
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs BDX Key Questions & Quantitative Answers

As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas BDX carries 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin). Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

BDX leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with BDX at -10.5% YoY revenue growth and +47.6% YoY earnings growth on $19.5B TTM revenue (47.0% gross margin, 15.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while BDX shifted +36.7%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 31.3% of Rev ($6.09B) (0 disclosures) for BDX.

BDX screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas BDX trades at 16.0x Forward P/E, 42.7x Trailing P/E, 0.99x PEG, and 4.2x EV/Revenue (19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus BDX (5.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, BDX carries 28.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.16β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.